Scholarlink

Purpose <p>To compare the effects of cyclosporine 0.05% and 0.1% in dry eye with Sjögren’s syndrome.</p> Methods <p>120 eyes of 60 patients who have been diagnosed with Sjögren’s syndrome were retrospectively enrolled. Thirty patients (group 1, 60 eyes) were treated with cyclosporine 0.1% and 30 patients (group 2, 60 eyes) with cyclosporine 0.05%. Ocular Surface Disease Index Questionnaire (OSDI), Schirmer I test, noninvasive tear break up time (NItBUT), corneal staining score, MMP 9, meibography, meibum quality and expressibility scores, tear meniscus height, and impression cytology were examined before treatment and at 1 and 3 months after treatment.</p> Results <p>All of dry eye signs and symptoms of both groups at 1 and 3 months were significantly improved compared with those before treatment, respectively (<i>P</i> &lt; 0.05). OSDI, Schirmer I test, NItBUT, corneal and conunctival fluorescein score, MMP-9 grade, goblet cell density, and impression cytology grade of group1 were significantly improved compared with group 2 at 1 and 3 months after treatment (<i>P</i> &lt; 0.05). The percentage of discontinued treatment in groups 1 and 2 was 26.7 and 3.3%, respectively.</p> Conclusion <p>Cyclosporine 0.1% was more effective for relieving inflammatory dry eye signs and symptoms but less tolerable compared with cyclosporine 0.05% in dry eye with Sjögren’s syndrome.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of effects of cyclosporine 0.05% and 0.1% in dry eye with Sjögren’s syndrome

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Donghyun Jee,
  • Su Yeon Han,
  • Hyun Seung Kim,
  • Eun Chul Kim

摘要

Purpose

To compare the effects of cyclosporine 0.05% and 0.1% in dry eye with Sjögren’s syndrome.

Methods

120 eyes of 60 patients who have been diagnosed with Sjögren’s syndrome were retrospectively enrolled. Thirty patients (group 1, 60 eyes) were treated with cyclosporine 0.1% and 30 patients (group 2, 60 eyes) with cyclosporine 0.05%. Ocular Surface Disease Index Questionnaire (OSDI), Schirmer I test, noninvasive tear break up time (NItBUT), corneal staining score, MMP 9, meibography, meibum quality and expressibility scores, tear meniscus height, and impression cytology were examined before treatment and at 1 and 3 months after treatment.

Results

All of dry eye signs and symptoms of both groups at 1 and 3 months were significantly improved compared with those before treatment, respectively (P < 0.05). OSDI, Schirmer I test, NItBUT, corneal and conunctival fluorescein score, MMP-9 grade, goblet cell density, and impression cytology grade of group1 were significantly improved compared with group 2 at 1 and 3 months after treatment (P < 0.05). The percentage of discontinued treatment in groups 1 and 2 was 26.7 and 3.3%, respectively.

Conclusion

Cyclosporine 0.1% was more effective for relieving inflammatory dry eye signs and symptoms but less tolerable compared with cyclosporine 0.05% in dry eye with Sjögren’s syndrome.